Induction Healthcare Group PLC Directorate Change (1967K)
May 04 2022 - 2:02AM
UK Regulatory
TIDMINHC
RNS Number : 1967K
Induction Healthcare Group PLC
04 May 2022
Induction Healthcare Group PLC
("Induction", the "Company", or the "Group")
Directorate Change
Induction (AIM: INHC), a leading digital health platform driving
transformation of healthcare systems worldwide, announces that Dr
Hugo Stephenson, who is based in Australia, will stand down from
his position as Group Executive Director, after seeing priority
ambitions for the Group realised during the period of pandemic
restrictions, and return to the Non-executive Director role he
originally held on admission to AIM in May 2019.
The Board change is a natural evolution of the leadership
structure in response to the strong trading position of the Group
at close of FY22, and the opportunities for face-to-face
interaction which are now possible for the UK based Executive and
Senior Management Team as borders re-open. It follows the
completion of the integration of the Attend Anywhere acquisition -
where most of the team was based in Australia - and the most
recently announced successful renewals of Induction Attend Anywhere
across NHS England. Both of these played a part in the positive
post-period end trading update of 21 April 2022 .
The Company has a dynamic UK based Executive Team in James
Balmain (CEO) and Guy Mitchell (CFO), who was appointed in November
2021 . James and Guy are supported by a strong Senior Management
Team, including Dave Williams, who joined as Chief Technology
Officer in September 2021 .
Hugo Stephenson commented: "James and his team have delivered a
really strong end to FY22, providing an exemplary outcome for
Attend Anywhere contract renewals, generating substantial demand
for Zesty as the NHS emerges from pandemic pressures, and
establishing a coordinated, global product and technology
organisation that is already demonstrating increased delivery
capability and cross-product efficiency under Dave Williams'
leadership.
From the outset I have imagined Induction Healthcare as an
enabler for flexible care around the world allowing healthcare
systems to offer patients and providers a range of digital and
in-person care options beyond the resource constrained 'bricks and
mortar' models historically available through hospitals. I stepped
into an executive role at the beginning of the pandemic - from a
locked-down basement in Australia - to provide Induction with
stability at a time of great global uncertainty and then a physical
link with the Attend Anywhere team post acquisition. My heart
remains in inspiring Induction to scale worldwide following the
impact we are already making in the UK. I am looking forward to
focussing on this mission which I can now do much more efficiently
and effectively from a non-executive position on our Board."
Induction CEO, James Balmain, said: "We are indebted to Hugo for
his immense contribution to the business since the commencement of
the pandemic during a period of uncertainty, changing rules,
opportunities and challenges. As we evolve and expand
internationally, I'm delighted that Induction will continue to
benefit from his experience and expertise. We all are incredibly
excited about the future prospects for the business."
- ENDS-
ENQUIRIES
Induction Via Walbrook PR Ltd: induction@walbrookpr.com
James Balmain, Chief Executive Officer
Guy Mitchell, Chief Financial Officer
Singer Capital Markets (Nominated
Adviser and Broker) +44 (0) 20 7496 3000
Philip Davies / Kailey Aliyar
Walbrook PR Ltd +44 (0)20 7933 8780 or induction@walbrookpr.com
Paul McManus / Alice Woodings Mob: +44(0)7980 541 893 / +44
(0)7407 804 654
About Induction - www.inductionhealthcare.com
Induction (AIM: INHC) Induction delivers a suite of software
solutions through a single integrated platform that transforms care
delivery. Our system-wide applications help healthcare providers
and administrators to deliver care at any stage remotely as well as
face-to-face - giving the communities they serve greater
flexibility, control and ease of access . Purpose-built for
integration with leading Electronic Medical Record (EMR) platforms,
our products offer immediate stand-alone value that becomes even
greater when integrated with pre-existing systems.
Used at scale by national and regional healthcare systems, as
well non-health government services, our applications are relied
upon by hundreds of thousands of clinicians and millions of
patients across almost every hospital in the British Isles.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAUPUUGAUPPPUW
(END) Dow Jones Newswires
May 04, 2022 02:02 ET (06:02 GMT)
Induction Healthcare (LSE:INHC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Induction Healthcare (LSE:INHC)
Historical Stock Chart
From Jul 2023 to Jul 2024